The Cleveland Clinic and five other universities in the U.S. have published the results of a large-scale AI drug discovery method to select effective drugs for Alzheimer’s disease from all FDA-approved drugs.
Fang J et al. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease. Alzheimers Res Ther. 2022 Alzheimers Res Ther. 2022 Jan 10;14(1):7. doi: 10.1186/s13195-021-00951-z.
As a result, three drugs were selected: pioglitazone, febuxostat, and atenolol. Clinical trials using pioglitazone have been conducted for Alzheimer’s and Parkinson’s diseases, but it has problems of patent expiration, hypoglycemia and bladder tumor.
We selected febuxostat by analyzing data from 2015, and patented a combination drug of febuxostat and inosine, which is now in clinical development at Takaha Pharma Co. Ltd. for the treatment of mitochondrial disease, Parkinson’s disease, and Alzheimer’s disease.
We had also considered the issue of patent expiration and patented a combination drug that is more effective and safer, and could be developed as a new drug.